The 35 references in paper A. Karabaeva Zh., M. Parastaeva M., O. Beresneva N., A. Smirnov V., A. Essaian M., I. Kayukov G., А. Карабаева Ж., М. Парастаева М., О. Береснева Н., А. Смирнов В., А. Есаян М., И. Каюков Г. (2008) “ВЛИЯНИЕ СПИРОНОЛАКТОНА НА ТЕЧЕНИЕ ЭКСПЕРИМЕНТАЛЬНОЙ ХРОНИЧЕСКОЙ ПОЧЕЧНОЙ НЕДОСТАТОЧНОСТИ И ГИПЕРТРОФИЮ МИОКАРДА У КРЫС WISTAR // THE INFLUENCE OF SPIRONOLACTONE ON THE COURSE OF EXPERIMENTAL CHRONIC RENAL FAILURE AND MYOCARDIUM HYPERTROPHY IN WISTAR RATS” / spz:neicon:nefr:y:2008:i:1:p:64-68

1
Смирнов АВ, Добронравов ВА, Каюков ИГ. Кардио­ ренальный континуум: патологические основы превентив­ ной нефрологии. Нефрология 2005; 9(3): 7-153
(check this in PDF content)
2
Шишкин АН. Современные проблемы уремической кардиопатии. Нефрология 2003; 7(1): 14-20
(check this in PDF content)
3
McMahon AC, Greenwald SE, Dodd SM et al. Prolonged calcium transient and myocardial remodeling in early experimental uremia. Nephr Dial Transplant 2002; 17(5): 759­ 7642
(check this in PDF content)
4
Кутырина ИМ, Руденко ТЕ, Швецов МЮ, Кушнир ВВ. Факторы риска сердечно-сосудистых осложнений у боль­ ных на додиализной стадии хронической почечной недо­ статочности. Тер арх 2006; 5: 45-50
(check this in PDF content)
5
Сторожаков ГИ, Гендлин ГЕ, Томилина НА и др. Пора­ жение сердечно-сосудистой системы при хронической по­ чечной недостаточности. Рос Мед Журнал 2005; 2: 4-8
(check this in PDF content)
6
Смирнов АВ, Добронравов ВА, Румянцев АШ и др. Факторы риска ИБС у больных, получающих лечение гемо­ диализом. Нефрология 2003; 7(приложение 1): 7-13
(check this in PDF content)
7
Amann K, Ritz E. Cardiac disease in chronic uremia: pathophysiology. Advanc renal replacement ther 1997; 4(3): 2212-2246
(check this in PDF content)
8
Ishikawa M, Akishita M, Kozaki K et al. Amino-terminal fragment (1-34) of PTH inhibits migration and proliferation of cultured vascular smooth muscle cells. Atherosclerosis 1998; 136(1): 59-66
(check this in PDF content)
9
Qing DP, Ding H, Vadgama J et al. Elevated myocardial cytosolic calcium impairs insulin-like growth factor-1- stimulated protein synthesis in chronic renal failure. J Am Soc Nephrol 1999; 19(1): 84-92
(check this in PDF content)
10
Dhein S, Rohnert P, Markau S. Cardiac beta- adrenoceptors in chronic uremia: studies in humans and rats. J Am Col Cardiol 2000; 36(2): 608-617
(check this in PDF content)
11
Hatori N, Havu N, Hofman-Bang C et al. Myocardial morphology and cardiac function in rats with renal failure. Jap Circ J 2000; 64(8): 606-610
(check this in PDF content)
12
Cortassa S, Aon MA, Marban E. An integrated model of cardiac mitochondrial energy metabolism and calcium dynamics. Biophys J 2003; 84(4): 2734-2755
(check this in PDF content)
13
Norris K, Vaughn C. The role of renin-angiotensin- aldosterone system in chronic kidney disease. Expert Rev Cardiovasc Ther 2003; 1(1): 51-63
(check this in PDF content)
14
Epstain M. Aldosterone as a mediator of progressive renal dysfunction: evolving perspectives. Intern Med 2001; 40(7): 573-583
(check this in PDF content)
15
Duprez D, de Buyzere M, Rietzchel ER, Clement DL. Aldosterone and vascular damage. Curr Hypertens Rep 2000; 2; 327-334
(check this in PDF content)
16
Wehling M, Spes CH, Win N et al. Rapid cardiovascular action of aldosterone in man. J Clin Endocrinol Metab 1998; 83: 3517-3522
(check this in PDF content)
17
Arima S, Kohagura K, Xu HL et al. Nongenomic vascular action of aldosterone in glomerular microcirculation. J Am Soc Nephrol 2003; 14(9):2253-2255
(check this in PDF content)
18
Fuller PJ, Young MJ. Mechanisms of mineralocorticoid action. Hypertension 2005; 46: 1227-1246
(check this in PDF content)
19
Epstein M. Aldosterone as a determinant of cardiovascular and renal dysfunction. J R Soc Med 2001; 94(8): 378-383
(check this in PDF content)
20
Nishiyama A, Abe Y. Aldosterone and renal injury. Folia Pharmacol Jap 2004; 124(2):101-109
(check this in PDF content)
21
Oberleithner H, Ludwig T, Iethmuller C et al. Human endothelium: target for aldosterone. Hypertension 2004; 43(5): 952-957
(check this in PDF content)
22
Jucknevicius I, Segal Y, Kren S et al. Effect of aldosterone on renal transforming growth factor-beta. Am J Physiol 2004; 286(6): F1059-F1062
(check this in PDF content)
23
Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbility and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717
(check this in PDF content)
24
Gross F, Rothstein M, Dombek S, Juknis HI. Effect of spironolactone on blood pressure and the renin-angiotensin- aldosterone system in oligo-anutic hemodyalysis patients. Am J Kidney Dis 2005; 46(1): 94-101
(check this in PDF content)
25
Harris C, Meyer T, Brenner BM. Nephron ablation to renal injury. The Kidney. Eds. Brenner BM, Rector FC. Philadelphia, London, Tokyo1986; 1555-1565
(check this in PDF content)
26
Okoshi K, Ribero HB, Okoshi MP et al. Improved systolic ventricular function with normal myocardial mechanics in compensated cardiac hypertrophy. Jpn Heart J 2004; 45(4): 647-656
(check this in PDF content)
27
Sevilla M, Voces F, Carron R et al. Amlodipine decreases fibrosis and cardiac hypertrophy in spontaneously hypertensive rats: persistent effects after withdrawl. Life Sci 2004; 75(2): 881-891
(check this in PDF content)
28
Rocha R, Martin-Berger CL, Yang P et al. Selective aldosterone blockade prevents angiotensin II/salt-induced vascular inflammation in the rat heart. Endocrinology 2002; 143: 4828-4836
(check this in PDF content)
29
Barr CS, Lang CC, Hanson J et al. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery diseases. Am J Cardiol 1995; 76: 1259-1265
(check this in PDF content)
30
London GM. Cardiovascular disease in chronic renal failure: pathophysiologic aspects. Semin Dial 2003; 16(2): 85­ 94
(check this in PDF content)
31
Rocha R, Stier CTJ, Kifor I et al. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology 2000; 141: 3871-3878
(check this in PDF content)
32
Struthers AD. Aldosterone an important mediator of cardiac remodeling in heart failure. Br J Cardiol 2005; 12(3): 211-218
(check this in PDF content)
33
Connell JCM, Davies E. The new biology of aldosterone. J Endocrinol 2005; 186: 1-20.
(check this in PDF content)
34
Cases A, Bragulat E, Serradell M et al. Endothelial dysfunction in chronic renal failure. Nephrologia 2003; 23(4): 42-51.
(check this in PDF content)
35
Weber KT. Targeting pathological remodeling. Concepts of cardioprotection and reparation. Circulation 2000; 102: 1342-1345 Поступила в редакцию 27.11.2007 г. Принята в печать 19.02.2008 г.
(check this in PDF content)